ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2025
Characterization of Microbial Profiles and Antimicrobial Resistance in Diabetic Foot Ulcers at a Tertiary Care Facility in Northern China.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Fungal detection, diagnostic approaches, and antifungal susceptibility in diabetic foot ulcers: a systematic review of recent evidence.Frontiers in fungal biology · 2026Pooled it
- Pathogen profile and inflammatory biomarkers in diabetic foot infections: correlation with disease severity.BMC infectious diseases · 2026Article
- [Epidemiological characteristics of adult inpatients with diabetes-related chronic non-healing wounds in Hainan province].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026Article
- Staged management of infected diabetic foot ulcers: a 300-patient cohort study on prognostic grading, pathogen dynamics, and individualized risk prediction.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThere are differences in the microbiological and antimicrobial patterns of patients with diabetic foot infections (DFI) in different regions. Understanding the microbiological and antimicrobial patterns of patients with DFI in this region provides a basis for the empirical use of antibiotics in clinical practice.
methodsThis study retrospectively analyzed the clinical and laboratory characteristics and microbiological and antibacterial patterns of patients with DFI from January 2016 to December 2023.
resultsA total of 697 patients were included, with the majority being male (63.4%), and ages ranging from 50 to 75 years (59.3%). Most had poor blood sugar control (70.3%). Among them, 527 (75.6%) had single microorganism infections, while 170 (24.4%) had multiple microorganism infections. A total of 891 pathogenic strains were isolated, of which 419 (47.0%) were Gram-positive bacteria (GPB), 454 (51.0%) were Gram-negative bacteria (GNB), and 18 (2.0%) were fungi. The most common GPB is Staphylococcus aureus (196, 22.0%), while the most common GNB is Proteus mirabilis (70, 7.9%). GNB infections and multiple microorganism infections were more prevalent than GPB infections and single microorganism infections in Wagner grades 3-4. Patients with GNB infections had higher levels of ESR, WBC, NE, NEUT, PCT, and CRP, while ALB and Hb levels were lower. GPB were highly sensitive to teicoplanin (100%), followed by vancomycin (99.6%) and tigecycline (99.2%); GNB exhibited high sensitivity to sulperazon and amikacin (100%), followed by ertapenem (98.8%) and meropenem (98.6%).
conclusionThe proportion of GNB is greater than that of GPB, primarily found in patients with moderate to severe DFI, who exhibit higher levels of inflammatory markers and more severe infections. However, S. aureus remains the most common microorganism in DFI. When using antibiotics, especially for patients with mild infections, coverage for common GPB, including S. aureus, should be considered, while for patients with moderate to severe infections, coverage should include common GNB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.